Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has appointed several key executives to strengthen its leadership team. Jenny Hsieh joins as Chief Strategy Officer, having previously led corporate strategy at Immunomedics. Sunitha Lakshminarayanan takes on the role of Senior Vice President, Head of CMC and Product Development, bringing extensive experience from Bristol Myers Squibb. Stephen Dressel is appointed Vice President of Strategic Finance and Analysis, with a background in finance at Regeneron. These additions come as the company prepares for pivotal clinical data results from the Iomab-B SIERRA trial and Actimab-A CLAG-M combination trial.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference on September 28, 2022. Chief Medical Officer Dr. Avinash Desai will join a panel discussing "Addressing Challenges in Cell Therapy and Transplant" at 9:00 AM ET. The conference will be held at the Lotte New York Palace Hotel, where Actinium's executive team will also be available for one-on-one meetings. The company is focused on developing targeted radiotherapies to improve cancer treatment outcomes.

Actinium Pharmaceuticals (NYSE: ATNM) provided a corporate update on September 21, 2022, highlighting key upcoming milestones in its clinical pipeline. Key data releases expected include topline results from the pivotal Phase 3 SIERRA trial for Iomab-B and overall survival data from the Actimab-A CLAG-M combination trial, both anticipated in Q4 2022. The company reported approximately $116 million in cash and equivalents as of Q2 2022, sufficient to support operations through mid-2025, facilitating its commitment to advancing targeted radiotherapies for patients with high unmet medical needs.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The hybrid event will take place at the Lotte New York Palace Hotel and online. Management will conduct one-on-one meetings and an investor presentation will be accessible on the conference and company websites. Actinium specializes in targeted radiotherapies for cancer treatment, with notable projects like I-131 apamistamab aimed at enhancing patient outcomes and reducing treatment toxicities.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented pivotal data from its Phase 3 SIERRA trial of Iomab-B at the TCT Meeting. The trial demonstrated that 100% of patients receiving Iomab-B accessed bone marrow transplants (BMT) compared to only 18% in the control arm. Additionally, Iomab-B showed lower rates of transplant-related mortality and sepsis. Notably, 82% of the control arm did not achieve the primary endpoint of durable complete remission. Topline results are anticipated in Q3 2022, aiming to bolster Iomab-B's position as a critical therapy for acute myeloid leukemia (AML) patients.

Actinium Pharmaceuticals (ATNM) is set to present updated Phase 3 SIERRA trial data at the TCT Tandem Meetings from April 23-26, 2022. This trial focuses on Iomab-B, a targeted radiotherapy designed for elderly patients with relapsed or refractory acute myeloid leukemia (AML), aiming for successful bone marrow transplants. Early data indicates a 100% access rate to transplantation and improved outcomes compared to conventional therapies. The findings will be showcased by Boglarka Gyurkocza from Memorial Sloan Kettering Cancer Center, highlighting Iomab-B's potential to revolutionize patient treatment pathways.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has entered a licensing agreement with Immedica for Iomab-B, an antibody-radiation conjugate aimed at treating acute myeloid leukemia (AML). Actinium will receive an upfront payment of $35 million and could earn up to $452 million in milestone payments, plus mid-twenty percent royalties on sales. Iomab-B is expected to facilitate bone marrow transplants, addressing a significant medical need in Europe, the Middle East, and North Africa. The Phase 3 SIERRA trial's topline results are anticipated in Q3 2022.